Soleno Therapeutics delivered exceptional third quarter results, with net revenues more than doubling to $66 million, culminating in a positive net income of $26 million as VYKAT XR establishes itself in the market as a crucial treatment for Prader-Willi syndrome (PWS).

• Achieved over 764 active patients on VYKAT XR six months post-launch, signaling strong market adoption.
• Total net revenue surged more than 100% from Q2, highlighting robust growth momentum.
• Despite a temporary disruption from a short seller report, patient engagement initiatives led to a rebound in therapy initiation as awareness and education advance.
• Ongoing preparations for a marketing authorization application in the EU could significantly expand the addressable market for VYKAT XR.
• Discontinuation rates remain below expectations, reflecting manageable safety concerns and effective patient management strategies.